Alnylam Pharmaceuticals Files 8-K Report
Ticker: ALNY · Form: 8-K · Filed: Mar 21, 2025 · CIK: 1178670
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: ALNY
TL;DR
ALNY filed an 8-K for 'Other Events' on 3/20/25. Details TBD.
AI Summary
On March 20, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Alnylam Pharmaceuticals has reported an event to the SEC, which could be material to investors. However, the specific nature of the event requires further investigation beyond this excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not, in this excerpt, disclose any specific negative or positive material information.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Filer of the 8-K report
- March 20, 2025 (date) — Date of the earliest event reported
- 675 West Kendall Street, Henri A. Termeer Square (location) — Principal Executive Offices address
- Cambridge, Massachusetts 02142 (location) — Principal Executive Offices city, state, zip
FAQ
What specific event is Alnylam Pharmaceuticals, Inc. reporting under 'Other Events' in this 8-K filing?
The provided excerpt does not specify the nature of the 'Other Events' being reported by Alnylam Pharmaceuticals, Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 20, 2025.
What is the principal executive office address for Alnylam Pharmaceuticals, Inc.?
The principal executive office address is 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142.
What is the SEC file number for Alnylam Pharmaceuticals, Inc.?
The SEC file number for Alnylam Pharmaceuticals, Inc. is 001-36407.
What is the IRS Employer Identification Number for Alnylam Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Alnylam Pharmaceuticals, Inc. is 77-0602661.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 21, 2025 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).